Discussion page for Arch Therapeutics (ARTH)This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
$ARTH atlas long
Yet another competitor enters the field:
UPM launches a new advanced wound care product for the European market. FibDex® is the first wound dressing created from wood-based nanofibrillar cellulose to receive regulatory approval and be awarded a CE mark. Nanofibrillar cellulose, which has been shown to be biocompatible with human cells and tissue, forms the core of the dressing. UPM’s proprietary nanotechnology, combined with over a decade of research into nanofibrillar cellulose and a highly professional R&D, has resulted in the development of this unique product.
http://inpublic.globenewswire.com/releaseDetails.faces?rId=2245243
yours, Finn
ARTH long. Corporate update.
https://finance.yahoo.com/news/arch-therapeutics-corporate-9th-annual-115000780.html
$ARTH Presentation LD Micro 6/4/19 by Dr. Terry Norchi plus my comments
1) On verge of commercialization. How many of your biotech investment positions are in the same situation? What is the risk here?
2) Planned revenue stream by End of Year. Building AC5 Inventory now.
3) Execute commercialization rollout and partnering strategy (in process now)
4) Multiple Selling Partner Strategy. Great news that there will be a different mix of partners between Europe and United States. Means there will be multiple partners and news announcements and possible up-front fees. This also means ARTH will be around for a while and not be acquired. Thus this will maximize ultimate buyout price. Intellectual property is now beyond FIFTY (50) patents. Big Positive.
5) Also mentioned significant interest out of Asia
6) Hired VP of development Dermal Applications (Wadsworth with deep ties to wound care space) to handle all the possible joint venture situations.
7) Mentioned focusing on Military opportunity for use of AC5
8) CE Mark should be any day now
9) Broad US (510 (k)) FDA clearance for external applications of AC5. Large external applications.
10) Submit clinical study IDE pre-submission for biosurgery–$6 $7 billion market opportunity
11) Cash burn is $ 1.9 million per quarter. Have approximately $ 4.2 million of cash.
12) 27,796,019 warrants outstanding with total exercise price of $ 18,0541101 8.9 million warrants at $ .25 share (in the money now)
13) Total Capital raised by ARTH since inception $ 33,778,723. Tiny !!!!!!!!!!!!!!!!!!!!!!!! The warrants are $ 18,054,101 or 53% of the total capital raised.
14) Even at the depressed market price –for every $ 1 raised by $ARTH it is worth approximately $ 1.72. Amazing.
15) Closure Medical Acquired by JNJ 2005 (comparable to ARTH—except ARTH has 10 times intellectual propery) $ 370 million. Market Cap of ARTH fully diluted is only $58 million or only 16 % of the $ 370 million. To get to $ 370 million ARTH would have to equal $ 1.71 per share.
$ARTH whale and long
Hi Cleveland – Thank-you for the update. A much needed morale boost.
Cheers – Todd
Thank you Cleveland much needed positve!
Thank you for sharing your comments, Cleveland. Very much appreciated.
$Arth OW Thanks again Cleveland!! If all goes as planned this is going to be huge!
$ARTH
The presentation is here:
http://wsw.com/webcast/ldmicro16/register.aspx?conf=ldmicro16&page=arth&url=http://wsw.com/webcast/ldmicro16/arth/index.aspx
The different revenue streams are going to be impressive. I love multiple selling partners. A lot of news throughout the year.
Remember the science has never changed.
What ARTH should be doing now is presenting to surgeon groups. They would be big buyers at this stage. We have had a big seller for some time now. Once their position is eliminated it should be clear sailing.
What are the risks at this point ?
Completely agree PLUS I have never heard Norchi so animated and high energy. The partnering talks must be going well, meaning no more capital raises. Relieved of that stress after 10 years, he sounded like he knows he’s riding a winning horse. For less than $35 million he’s gone from nothing but a patent to an FDA-approved product with the CE Mark imminent. I’ve been investing in biotech since Genentech went public and I’ve never seen anything like it.
JohnM Me too. Since 2006 Norchi has been waiting and planning for this day. We are going to see a flood of press releases over the next year. ARTH=cheap, hated and in an uptrend. The perfect storm.
Careful; if Cleveland is back pumping there is almost certainly a secondary offering around the corner!
** UNCALLED FOR**
Well it’s true. He is not allowed to talk about it @ pumpanddumpbiopubkss.com so he is pumping it here. That’s integrity for you.
Do you know the definition of integrity, enough consider the source.
That’s exactly what it is – lack of integrity. So he is some sort of a board member at the Biopub and $ARTH is no good there but it is an investment of a lifetime here.
exactly; $ARTH talk is banned there because it is viewed as a scam. Hey Griffin, how often does Cleveland post on here to guide you? Does it involve any other ticker than $ARTH? Open your eyes
Exactly what I was going to say. He writes about $APTO there yet I haven’t seen him sharing anything on that company here. So he risks KSS’s wrath by posting on $ARTH here yet he won’t share any insight on other previously discussed tickers here. You gotta question the motives.
This page is for ARTH discussion….why would you expect Cleveland to post on any other ticker? I always trust and admire Cleveland and have never seen any ulterior motive in his posts…he spends a lot of time analyzing companies for us and I appreciate all his posts!
IMHO, there were certainly previous members who took advantage of their influence with this forum and the frailties of micro bio’s, KSS and Helen being 2 of the most infamous, but I believe that Cleveland has always been a straight shooter.
Cheers – Todd
Cleveland took more of an advantage than anyone IMO by using the platform to pump $ARTH for his own financial reasons. Downvote me if you want but please ask Cleveland to disclose his financial relationship with $ARTH beyond being long shares
ReeEEEeee!!!
Why is underwater ARTH warrants Cleveland “regis999” on Investorshub, “Brinkstruck” on Seeking Alpha, and “John” on Yahoo Finance posting the same verbiage? Why structure the arguments in the form of a pump and dump newsletter imploring an investment rather than just factually based allowing readers to decide? Is JohnM a Cleveland sockpuppet account?
Very sketchy fact pattern; if you want to rally around the umbrella man in the Twilight Zone episode feel free to do so.
One last question: if Cleveland is your “friend” why does he just come around to pump every 3 months or so?
I personally don’t question the integrity of Cleveland. The fact that he posts on different forums with different usernames doesn’t bother me. I tend to not do it because I can post on a few different forums regarding unrelated topics so it is easier for me to remember one name. Especially because I don’t post that often. And this forum has slowed dramatically. So it isn’t necessarily surprising he or whoever only comes back on good news. Having said that. This thing can all be settled by Cleveland coming on here and putting up one paragraph. Or less. “Hey. Here is what my relationship with ARTH is”. Obviously he has followed it much more closely then most and has attended some of the stuff. But it may and probably will be – “I am just a stockholder on the internet like you. I don’t have inside information and am not pumping and dumping”. And again. I don’t question his integrity. But apparently some do. That is why I think it is best for Cleveland to clarify and I am sure put this to rest right now. So there is no cloud hanging over his head.
Where do you get the authority to make such a statement? If you think that due to recent developments within the company and comments made by several folks, indicate an ulterior motive exists, why pick one name to hang it on? It’s comments like this that ruins a good forum.
ARTH completed an offering of $2.8 million on May 13. There is no way another offering is around the corner.
Playing devils advocate… their cash burn is at what, 1.9 mill per quarter? I don’t have the slides in front of me, but I believe they had just over 4 million of cash on hand (including last dilution). That puts us at 6 months til runout. No partnership and no revenue stream by end of August puts us back in dilution talks. Not so far fetched. (OW and long BTW)
Wanna bet money? Check out prior pumps here relative to secondary offerings
This thread is a few years old……anyone can start at the beginning to read the comments. Travis may have a previous thread that Lynn can forward, not sure but this is not the first time Cleveland’s integrity has been challenged in regards to ARTH. Many gummies held positions and road the wave, after wave, those who got in below .19 are probably still ‘green’……Look up how much these CEO take home, the burn each 1/4 and match that to new stock offers. I wish everyone holding the best. May this be your 10 bagger. It’s kind of similar to Cdn mining stocks……
Oh Jeffrey M here, Dangerb407 at Seeking Alpha and just plain Jeffrey everywhere else. My you leave a wide path.
So much misinformation and total nonsense all in the attempt to stifle any real discussion of Arch.
For example you posted at one of the other hoods:
“Cleveland every time you start pumping this stinker they do a secondary offering shortly thereafter. Not everyone knows the full history of your shenanigans on Stock Gumshoe, for example. That is my addition! ”
“I exited $ARTH last week because of concerns about TN’s ability to execute in a timely manner and I still made a profit overall given earlier position sales in validation of some of Cleveland’s earlier points.”
No longer “blessed?” So you profited from the actual discussion of Arch. Many here got in at $.19 and $.20 and either profited or are still holding at a profit.
So according to you I post once a quarter here. Somehow that is tied to Arch doing a private placement once a year. Really. Makes no sense.
Somehow posting once a quarter is pumping? Very weird.
For years here I have stated over and over and over that I do not care whether anyone owns Arch. Do not care. Further proof is I voluntarily agreed to not discuss Arch on BioPub because I do not care. I alone initiated this.
Dr. KSS walks on water. No one cares more or works harder than him. End of Story. I have defended him here numerous times. I will continue to do so.
I have no insider affiliation with Arch. None.
Now that I know who you are and what you are I look forward to spending more time with you. You obviously want and need attention.
Please stop stifling the discussion.
you have a bunch of underwater warrants that you are trying to monetize. That is a fact. Good thing that you have a following for your quarterly pied piper posts! And yes, I did make money on ARTH by selling in the 80s but would be (way) underwater if I held on the way back down. I sold in the 80s; what is the share price now? Why do you continue to lead people astray? KSS has said that this is a dog. Is he lying?
See you in September! I don’t want your attention as I would need to guard my wallet the whole time. Sad!
JMBanks Good question. I am working on it. Thanks
I do not post much but I found it important when I came across the negative posts aimed at Cleveland. He is one of the few posters IMO that adds value and stays on point with the subject. If you are an ARTH investor, you are fortunate he provides updates and his analysis as events unfold. I have been following his posts for years and, IMO he has no hidden agenda. I appreciate his expert opinions on Arch and the rest is up to me. I am glad he is back on Gumshoe, since Arch is no longer discussed on BioPub. Keep up the good work Cleveland!!
Cleveland is the straight shooter here!
Yes he’ll be back in 3-6 months
Charles Mary Apple Thank you so much for your very kind comments. For years I have tried very hard to be helpful. I just want to help people do their own due diligence. My due diligence is never ever done. I never cared whether you own or not. That is your business not mine. I have a blue collar heart and a white collar mind. My father was a bricklayer.
my thoughts exactly!
somebody giving you DD for _free_ does not release you from your responsibility to do your own. not everybody seem to understand this critical part of investing and they get upset for the one who did the job for you. how sad is that? enough of biting the hand that feeds you.
all the thanks to Cleveland, please keep up the good work and ignore the rest.
yours, Finn.
A fool and his money… the real profit would be in internal applications. Where are they on that front?
Jeffrey M
Back for more. Just will not let us discuss ARTH.
Five years I have been discussing ARTH. Get lost !
Remember he is just plain Jeffrey on the Pub.
https://www.stockgumshoe.com/2017/11/microblog-discussion-page-for-arch-therapeutics-arth/comment-page-3/#comment-4998656
Cleveland – Happy Father’s Day! A good day to ignore aholes and trolls, just like the other 364 days a year. Illegitimi non carborundum.
The wound care applications for AC5 are huge. Hospitals don’t get reimbursed for treating bedsores, a “preventable” problem according to Medicare (sure, if you can dedicate large amounts of scarce nursing time – which isn’t reimbursed, either). AC5 can take care of bedsores.
And don’t get me started on diabetic foot ulcers – first a partial amputation of the foot, then rehab, then back for a complete amputation of the foot, then more rehab, then a partial amputation of the leg, more rehab, probably a wheelchair…or aggressive debridement up front, AC5, and problem solved. Gee, I wonder what Medicare would pay to stay out of that downward spiral?
JohnM Good to hear from you !! Happy Father’s Day !!
It was your great comments on ARTH in 2014/2015 was got me interested in ARTH. Thank you !!
I started looking into ARTH Ophthalmology and Inflammation applications. Imagine joint venture partners here.
Inflammation applications: psoriasis,etc
Ophthalmology applications: Corneal erosions, dry eye disease, retinal detachment, vitrectomy and contact lenses
Regarding the May private placement historically ARTH has sold to three instiutions that flip their shares at a profit and hold their warrants. I tried to find out who did the private placement but was not successful. Soon the selling pressure will be past.
Commercialization next.
Cleveland, Jeffrey M is collecting negatives so if and when Travis brings them back he will have cornered the market. 😉
Yes, about the thumbs up/thumbs down – where did they go to? I was away from my computer for a few weeks on vacation, and when I come back: Poof! They’re gone!
If you don’t understand the financial motivations for Cleveland’s posts (underwater warrants that he is trying to monetize) you are going to lose (more) money. You’d be better off gifting to Cleveland directly; you could deduct $10,000 of it per year!
Jeffrey – Whether Cleveland buys, owns, or sells ARTH will have no impact on the fundamentals of the company. I am holding ARTH long term for $10 to $12 a share either based on their royalty streams or a buyout. Cleveland’s perspective is very welcome here, and I’d appreciate it if you would stop the ad hominem posts.
JohnM – Happy Father’s Day to you and Cleveland and all the other Dads out there in the Gummopolis (NOT similar to that great older movie “Metropolis”. Watch it if you can.)
I’ve been a little more modest in my outlook – I’ve been hanging in there for an $8 buyout.
And of course, like everyone else I’m wishing development of whatever end uses there are, would be a little speedier. Otherwise I’m going to have to leave specific instructions to my heirs that they are NOT to sell $ARTH, sigh.
$ARTH Long
This is so interesting.
Closure Medical—Marketing Agreements–Note Up Front licensing fees BEFORE regulatory approvals
“On March 20, 1996, the Company entered into an eight-year exclusiv supply and distribution rights agreement with Ethicon whereby Closuresupplies Ethicon with DERMABOND, a product for human topical wound closure. In consideration, Ethicon paid Closure $4,500,000 of which$3,500,000 was a non-refundable licensing fee and $1,000,000 has been and will continue to be offset against either future product purchasesor royalties to be paid by Ethicon on product sales and has been classified as deferred revenue on the accompanying balance sheet. With the United States and European Community approval of DERMABOND in August 1998 and 1997, respectively, Ethicon is obligated to purchase certain minimum quantities annually at a predetermined price based on average selling prices.”
“DERMABOND(R) adhesive was cleared for marketing by the United States Food and Drug Administration (“FDA”) in August 1998.”
Note that sales began after August 1998.
JNJ acquired Closure Medical 3/3/05 for $ 370 million. Through 12/31/04 Closure had raised $ 65.7 million from inception. Went public 9/25/96. Approximately 8 years until acquired by JNJ.
ARTH has a market cap of $56.05 and has raised $ 33.8 million from inception and went public May 20, 2013. Thus six years
$ARTH large and long
Cleveland – thanks again for the info. Much appreciated! I truly believe our patience will pay off handsomely.
Cheers – Todd
$ARTH Long
Let me do a verbal interpretation of the above because ARTH is following the exact template of Closure.
Closure did the JNJ Marketing arrangement BEFORE going public AND before getting regulatory approvals. This juiced their IPO event having JNJ on board in the marketing agreement. The fact that JNJ was willing to put upfront fees of $ 4.5 million is amazing. Having JNJ on board from the get go made financing simple IMHO.
Closure Medical Revenues 12/31
2000 $ 13.076 million
2001 $ 18.405 million
2002 $ 22.711 million
2003 $ 33.933 million
2004 $ 39.691 million
Johnson & Johnson acquired Closure Medical 3/3/05 for $ 370 million.
IMHO JNJ caused the 2004 slight downfall in revenues. They controlled the books.
Closure Medical—Marketing Agreements– Ethicon, Inc, Johnson & Johnson Consumer Products Company, Colgate Oral Pharmaceuticals, Inc and Abbott Laboratories, Inc. all contributing to R&D expenses. IMHO ARTH will have numerous marketing agreements
How many will ARTH have?
ARTH’s market cap of $ 56.05 is only 15% of the $ 370 million that Closure was sold for. 15% !!
ARTH has achieved FDA approval of AC5 at a fraction of the cost that Closure incurred. ARTH has raised “only” $33.8 million versus Closure’s $ 65.7 million.
AC5 has over 200 applications. How many marketing agreements will there be? Closure medical applications were narrow compared to ARCH.
Also as to Arch Ophthalmology and inflammation (psoriasis,etc) applications.
As to Ophthalmology applications: Corneal erosions, dry eye disease, retinal detachment, vitrectomy and contact lenses. Many more marketing agreements coming.
More later.
Arch Therapeutics (ARTH) Versus Closure Medical
Corporation Overview: Arch has been compared to Closure Medical which was acquired by Johnson & Johnson for $ 370 million in March 2005. Arch’s present market cap is only 15% of Closure’s acquisition price of $ 370 million. Arch’s positive differences with Closure are overwhelming as summarized below.
Arch Therapeutics with only 8 employees headed by CEO Dr. Terrance Norchi and with “only” $33.7 million of cash capital raised since inception received FDA approval to market its noncoagulant homostatic agent called AC5 for external applications with over 200 applications including Diabetic foot ulcers, Pressure Ulcers (bedsores), Adhesions, GI Sealant and Burns, etc.
Dr. Norchi is a MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund and the largest shareholder and founder of Arch Therapeutics.
Closure Medical Corporation
1) JV Johnson & Johnson 3/30/96 BEFORE IPO AND BEFORE REGULATORY approvals with $ 4.5 million up front fees
2) IPO 9/26/96 at $ 8 share with a initial market cap of $ 48 million
3) In 1996 Closure completed an 818-patientcontrolled, randomizedclinical trial of DERMABOND at ten sitesthroughout the United States. (Arch’s human clinical trials have all been small with less than 50 patients at ONE location)
4) August 1998 Dermabond adhesive was cleared for marketing by the FDA
5) 12/31/04 Closure had raised a cumlative total of $ 65.7 million since inception (Sold for $ 370 million or 5.6 X). (Arch Therapeutics total cumulative raise since inception is $ 33.8 million)
6) 3/3/05 Johnson & Johnson acquired Closure Medical Corporation for $ 370 million or $ 27 share ( 3.3 X the IPO price) some 8 years after going public.
7) Closure 1999 75 employees with Fourteenmembers of the Closures research and development staff have doctoral or advanced degrees. (Arch last 6 years 8 employees—only 3 with doctoral)
8) Closure Revenues 2004 $ 39.691 million Pre-tax income $ 13.78 million 35% of revenues—-123 employees with Fifteen members of the Closure’s research and development staff having doctoral or advanced degrees.
9) Closure Research & Development Costs 12/31 1996 $ 3.167 million 1997 $ 3.594 million 1998 $ 6.297 million 1999 $6.296 million 2000 $ 5.852 million 2001 $ 5.622 million 2002 $ 6.436 million2003 $ 8.134 million 2004 $ 10.01 million (Arch highest R&D in last six years is only $2.9 million—is not Arch’s highest R&D behind now?)
10) Closure’s cash grew to $ 51.020 million ( 13.7 % of $ 370 million acquisition cost by JNJ) at 12/31/04 up from $11.3 million at 12/31/99. Business was a cash cow despite the heavy employee count. What will Arch be with so few employees?
How did Arch Therapeutics develop its superior technology on a “shoe-string’ budget for six years with only eight employees?
Two reasons
1) Arch’s Business Model
2) Arch’s secret weapon, Dr. Steven Kates who has worked with Arch since 2007.
Dr. Kates is regarded as a world leading chemist and industry expert in peptide design and manufacture in the biopharmaceutical industry.
“ARCH Business Model
Our present business model is to operate with a relatively small internal team of key personnel and engage third party service providers to conduct larger scale research, development and manufacturing activities.
Our internal team collectively has a broad range of expertise and experience working with and managing third party vendors. This general approach enables us to use the services of third party entities, which are expert in various aspects of our operations, while preserving capital and efficiencies by avoiding certain internal scale-up costs and resource duplication.”
Arch’s Business Model is the exact opposite of Closure Medical. Arch for last 6 years has had only 8 employees—only 3 with doctoral degrees.
What will this business model mean as ARCH commercializes? Arch’s manufacturing costs are extremely low. Per Dr. Norchi AC5 will be at a premium pricing strategy at $200 to $1,500 unit. Thus margins should be broad
JohnM How do you interpret the above? Does it not help explain a lot?
On a different topic, but still biotech, I was surprised by the sharp rise in $CAPR share price today. From Marketwatch:
https://www.marketwatch.com/story/capicor-therapeutics-stock-rockets-on-heavy-volume-after-positive-md-trial-results-2019-07-15?mod=mw_quote_news
“Shares of Capricor Therapeutics Inc. CAPR, +93.48% nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat results from a trial for its treatment (CAP-1002) of Duchenne muscular dystrophy. Trading volume was about 1.7 million shares ahead of the open, compared with the full-day average of about 56,500 shares. “I am incredibly pleased with the outcome of the interim analysis as it has demonstrated the biologic activity of CAP-1002 that has resulted in changes of clinically relevant outcomes including the upper limb, the hand and diaphragmatic function,” said Craig McDonald, the principal investigator for the trial. The stock has lost 42.6% over the past three months through Friday . . .”
Alas, I have but a minuscule holding, even more minuscule after the 1 for 10 reverse stock split on June 5th this year.
After the Capr split, my average share price is 20.00….ouch!
But it’s a 10 bagger from here! Don’t you know ? 😉
I hope I can post an off topic Biotec I found this a few months ago and now it is beginning to get interesting. IIRC Biotec devices have shorter trial sizes. They spent 6 years with one of our National Labs developing an iron particle small enough to be coated with a biotec medium that attaches to a cancerous growth.
$ASX:IBX – Imagion Biosystems Receives FDA Breakthrough Device Designation
“Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, today announced that it has received notification from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer has qualified for and been granted designation as a Breakthrough Device.”
https://mailchi.mp/imagionbio/fda-breakthrough-device?e=a1d2906b31
ASX:IBX long
Per ARTH 10Q on timing of CE mark: “Given the recent changes in the governing rules and the impact of Brexit, the review process has taken longer than anticipated. We now currently expect that the review process to be completed this fall.”
$ARTH – Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
https://ir.archtherapeutics.com/press-releases/detail/527
AC5 keeps getting better “Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body”. CE approval this Fall maybe not much longer.
ARTH long
$ARTH Long
A nice press release – so a question for you all about their statement – “As a result, we currently expect the review process to be completed this fall, and we anticipate our next update to coincide with a definitive and material announcement.” So, what does TN mean by “our next update? ” Is that the monthly update they seem to make about the company or the next time they talk about the CE application? I really like this part “to coincide with a definitive and material announcement”. That seems to be really a positive statement that portends good news is a coming.
I’m not aware of any scheduled updates I’ve signed up for their newsletters, as I do with most all companies I’ve invested in, there are no scheduled updates that I’m aware of. I would think that they are working on one because this is the first I’ve heard of the antimicrobial and that needs to be elaborated on. I won’t guess as to which comes first CE approval or more antimicrobial data. Right now I’m just hoping it’s before November there are others more informed than I.
The definitive material announcement is going to be more dilution and more delays.
So are you going to sell the stock?
I don’t know, but I think anyone who’s been invested in this stock for years like I have should be concerned. How are you feeling about their financial position and their ability to raise money now in comparison to the post below from you a year ago, do you think this is still on track?:
I worry a lot more about biotech companies that can’t raise money than those that can. This $4.5 million will carry ARTH into the December 2019 quarter, so we will get the results of the sensitization study, the 510(k) filing, the CE Mark filing, the 510(k) approval, the CE Mark approval, and the IND filing for internal use before he needs to raise money again. Actually, I expect him to sign a distribution deal in 2019, if only for Europe, that should provide enough upfront cash to avoid any more stock sales.
Pretty much the same. The (unnecessary) sensitization study was good, the 510(k) was filed on time, the CE Mark was filed on time, the 510(k) was approved, the CE Mark approval is next, and the IND will be filed before he needs to raise money again.
Given the CE Mark delay, I don’t know if there’s time to sign a European distribution deal before he needs to raise money. He may squeeze by with warrant exercise proceeds if the CE Mark pops the stock enough.
In the meantime these Yahoo!’s collect $500,000 salaries. Send out a sentence or two every few months and ask for more money every few years.sheesh people. ???
Quite a good summary of Arch Therapeutics in Seeking Alpha
https://seekingalpha.com/article/4285493-examining-next-arch-therapeutics
yours, Finn
Anybody watch the Arch presentation yesterday. I missed it. Norci say anything new. Need something to get this stock to move. Thanks
Anyone hear ANYTHING at all? All I’ve heard is the sound of the SP dropping every time I check in online. 0.2675 today. I think that may be at or near the lowest it’s been since I’ve owned it (Summer 2015). Cleveland, any news?
Listen to the Wainwright presentation.
When was that, JohnM? Is it something new?
Monday, September 9. The presentation and webcast audio are at https://ir.archtherapeutics.com/presentations
Have you located the unicorn yet?
$ARTH-l-ow-my current average price is $0.29. Last week, the stock appeared to open at $.20/share on high volume. Yesterday it appeared to open at $0.15/share. My offer on both days prior to open was $0.23 but, I did not fill at the lower levels which implies that these were private pre-planned transactions at $0.20 and again at $0.15. Does anyone have an idea what actually happened and whether it is bullish? bearish? neutral? for the stock going forward?
How are fills at $0.20 possibly bullish?
Capitulation?
https://ir.archtherapeutics.com/press-releases/detail/529/arch-therapeutics-provides-corporate-update-at-the-2nd
$ARTH – Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
“On the regulatory front, as stated in the press release issued on October 2, 2019, Arch awaits acknowledgement that the notified body has completed its review process, and the next update is expected to coincide with a definitive and material announcement. No additional data has been requested by the Company’s notified body”
https://ir.archtherapeutics.com/press-releases/detail/529
ARTYH long
$ARTH
Can someone help me out here? I am having trouble parsing the above statement, which is similar to one that was made about a month ago. What is throwing me are the words “next update” and “coincide”? First, “next update” – is that Arch’s next update to us or the notifying body’s update to Arch? Second, “coincide” – does this mean that Arch will have a definitive and material announcement or is it the notifying body’s update that will have a definitive and material announcement? This “coincide” part has me both worried and excited at the same time. The worried part mirrors a post someone made when the statement first was used about a month ago, that TN will use the stock price bump to sell more stock to dilute our stakes. I hope this is not the case as I would believe that any deals signed would provide upfront capital for Arch, but it is in the back of my mind. The excited part is of two flavors – Flavor one is that the definitive and material announcement is from the notify body that they have approved the CE. Flavor two, which is based on the other part of the announcement in the link provided by Griffin, is that with the CE approval there will be announcements of deals with distributors to finally get AC5 out into the market place and at the same time put money in Arch’s pocket. Although Arch in their statement indicated that it takes a lot of time to iron out the details of each deal as the reason that no deals have been signed yet, I am assuming that the CE mark will be the catalyst to getting the deals completed.
So I know that there are greater minds out here then mine, can anyone help me out?
I received two news releases yesterday the first one;
https://ir.archtherapeutics.com/press-releases/detail/529
the second one;
https://ir.archtherapeutics.com/press-releases/detail/530
I read both but did not see that there was a significant difference so did not post the second think there was only an error correction. I did not print one out and compare it to the other to pinpoint the difference. It appears there has not been any change in the CE approval we are still waiting.
Why hasn’t Cleveland been back to pump this stinker?
JAM is harassing. insulting, bullying and stalking ethical as CFA and under your employment? I have ALL your posts from multiple sites. I am not a CFA.
Also have several friends at your Firm.
From the “Rock” in Glen Rock
who is JAM Cleveland and what is this all about?
I assumed he (Cleveland) is referring to Jeffery M? I have no idea what Cleveland’s post is referring to however.
sounds threatening; glad I got a screenshot! Seems to be going WWE with some random Rock reference.
Suggested solution: Don’t pump penny stocks from the 70s down to the teens and I won’t call you out
LOL at the downvotes from people who have been doubling down on the way down based upon someone pumping a penny stock. SMH